Cisplatin
CAS number: 15663-27-1
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Related images
Macsynergy plots of 45 with cisplatin in HCT116 cells (a), cisplatin in HFL1 cells (b), IR in HCT116 cells (c), and IR in HFL1 cells (d).
Synthetic route for the preparation of 4a−e from cisplatin: (a) 30% H2O2, 50 °C; (b) succinic anhydride, anhydrous DMSO, room temperature; (c) R−N=C=O, anhydrous DMF, room temperature
Platinum intracellular accumulation in HeLa cells after 3 h continuous exposure to cisplatin, 1a and 1b, administered at the same concentration (1 lM).
Related Questions and Answers
A: Cisplatin is a platinum-based chemotherapeutic agent that plays a crucial role in both dd-MVAC and GC regimens by inducing DNA damage, leading to cell cycle arrest and apoptosis in cancer cells. Its presence enhances the overall efficacy of the regimens in reducing tumor size and improving patient outcomes.
A: Cisplatin is an essential chemotherapeutic agent in the aMVAC regimen. It helps achieve complete pathological responses in patients with muscle-invasive urothelial cancer. A study found that any reduction in the cisplatin dose significantly decreased the likelihood of achieving a complete pathological response.
A: A maximum of eight 21-day cycles of gemcitabine plus cisplatin; thereafter, only durvalumab monotherapy continues.
A: Cisplatin 25 mg/m² IV on Days 1 and 8 of each 21-day cycle for up to eight cycles.